• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, July 9, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Researchers compare drugs for treating severe hypertension in pregnancy

Bioengineer by Bioengineer
July 5, 2018
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A recent meta-analysis of published studies has compared the efficacy and safety of antihypertensive drugs during pregnancy.

In the British Journal of Clinical Pharmacology, investigators reported similar efficacy between nifedipine, hydralazine, and labetalol, and negligible differences were observed in their safety profile. The available evidence was inadequate for other drugs. Moderate quality of evidence was observed for direct comparison estimates between labetalol and hydralazine, but was either low or very low for other comparisons.

Labetalol, hydralazine, and nifedipine are likely comparable for treating acute-onset, severe hypertension in pregnancy, noted the authors, Dr. Kannan Sridharan and Prof. Reginald Sequeira, of Arabian Gulf University, in Bahrain.

###

Media Contact

Josh Glickman
[email protected]
201-748-6572

http://newsroom.wiley.com/

http://dx.doi.org/10.1111/bcp.13649

Share12Tweet8Share2ShareShareShare2

Related Posts

LINC01929 Drives Breast Cancer via TFRC-Linked Ferroptosis Pathway

July 9, 2026

Epitope Editing Enables Safe Transplantation and In Vivo Cell Selection

July 9, 2026

Study shows lung tumors hijack nervous system to starve body

July 9, 2026

Former ONTPD Chairs Reflect on Two-Year Fellowship Proposal

July 9, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13
  • 高齢者の骨粗鬆症治療の持続性比較

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

LINC01929 Drives Breast Cancer via TFRC-Linked Ferroptosis Pathway

Epitope Editing Enables Safe Transplantation and In Vivo Cell Selection

New Method Enables Electrical Control of Helimagnetic Structures

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 84 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.